Scientists talked about the possible acceleration of aging after chemotherapy
Some chemotherapy regimens that increase breast cancer survival may accelerate biological aging. Researchers from the United States have built a model to assess how treatment-related cellular changes can affect health years later. The model showed a more pronounced effect for anthracycline-based schemes. About how the researchers estimated the biological age after treatment and where the difference of 9.4 years came from in their calculations, see the Izvestia article.
How was the biological age estimated
The calendar age shows how many years have passed since birth. To assess biological age, scientists use indicators that reflect the state of cells and tissues. The authors of the work took as a basis the level of messenger RNA, according to which cells produce the protein p16. This indicator is used as a marker of cellular aging. Senescent cells stop dividing and can persist in tissues, releasing substances associated with inflammation.
The scientists used data from previous clinical studies on how the level of this marker changed after different chemotherapy regimens. Then they calculated how the indicators could change over the rest of their lives.
"In our methodology, we take into account that chemotherapy increases the survival rate of breast cancer and at the same time can increase damage to healthy tissues," explained lead author of the study, Swarnavo Sarkar, a researcher at the Institute for Cancer and Aging Research at Georgetown University.
Where did 9.4 years come from in the calculations?
The authors modeled two scenarios for American women who were diagnosed with breast cancer between the ages of 30 and 79. In one scenario, all women received anthracycline—based regimens, in the other, less cytotoxic regimens without them. The simulation results were compared with data from ABC clinical trials in early breast cancer. The model reproduced the picture of the first eight years of observations. With anthracyclines, the risk of death from breast cancer was lower, and overall survival over this period was comparable.
For the anthracycline regimen, based on calendar age, life expectancy after diagnosis was 34.4 years. When accelerated aging was included in the model at the level corresponding to the middle of the distribution, the estimate was 25 years. The difference between the two calculations for the same scheme is 9.4 years. For the anthracycline-free scheme, the same difference was 1.8 years.
The model showed the greatest difference for women who were diagnosed at 30-39 years old. For the anthracycline regimen, the calculated indicator in this age group changed from 50.4 to 38.7 years after diagnosis. One of the reasons given by the authors is a longer period of life after treatment, during which aging—related changes could occur.
The model also allowed us to estimate when the cumulative risk of death from other causes becomes higher than the risk of death from breast cancer. Based on calendar age, this occurred 33 years after diagnosis. Taking into account accelerated aging in the anthracycline scenario, the tipping point occurred 16 years earlier according to the median estimate.
What needs to be checked after the end of treatment
The calculation depends on the assumption that the shift in the cellular aging index persists after treatment and is not compensated over time. It will have to be tested in long-term observations with repeated measurements. In this work, one biomarker was used for evaluation. The authors did not perform separate calculations for radiation, hormonal, targeted, and immunotherapy.
The authors emphasize that when choosing a scheme, survival in breast cancer remains a priority. The next question concerns the period after the end of therapy. The researchers want to find out which indicators of aging make sense to track, who they help predict health problems for, and whether this data can be used to plan follow-up.
Переведено сервисом «Яндекс Переводчик»